Accolate is a brand name of zafirlukast, approved by the FDA in the following formulation(s):
ACCOLATE (zafirlukast - tablet; oral)
Manufacturer: ASTRAZENECA
Approval date: September 26, 1996
Strength(s): 20MG [RLD][AB]
Manufacturer: ASTRAZENECA
Approval date: September 17, 1999
Strength(s): 10MG [AB]
Has a generic version of Accolate been approved?
A generic version of Accolate has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Accolate and have been approved by the FDA:
zafirlukast tablet; oral
Manufacturer: DR REDDYS LABS LTD
Approval date: November 18, 2010
Strength(s): 10MG [AB], 20MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Accolate. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Crystalline form of indole derivative and pharmaceutical method thereof
Patent 5,294,636
Issued: March 15, 1994
Inventor(s): Edwards; Martin P. & Sherwood; John D.
Assignee(s): Imperial Chemical Industries plc
A physical form of N-[4-[5 -(cyclopentyloxycarbonyl)amino-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl ]-2-methylbenzenesulphonamide substantially free of other physical forms, which form is crystalline, has an X-ray powder diffraction pattern with specific peaks occuring at 2.theta.=8.1, 13.7, 16.4, 20.5 and 23.7.degree. and an infra-red spectrum (0.5% in KBr) having sharp peaks at 3370, 1670, 1525, 1490, 1280, 890, 870 and 550 cm.sup.-1, a process for its preparation and pharmaceutical compositions containing it. Also disclosed is a flowable preparation of the physical form which is in the form of soft pellets, and a process for obtaining this preparation.Patent expiration dates:
- December 11, 2011
- December 11, 2011
Pharmaceutical agents
Patent 5,319,097
Issued: June 7, 1994
Inventor(s): Holohan; James J. & Edwards; Ieuan J.
Assignee(s): Imperial Chemical Industries PLC
The invention provides a pharmaceutical composition comprising a particular physical form of N-[4-[5-(cyclopentyloxy-carbonyl)amino-1-methylindol-3-yl-methyl]-3-methox ybenzoyl]-2-methylbenzenesulphonamide and polyvinylpyrrolidone. It also provides methods for preparing this physical form, and another physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyll-2-methylbenzenesulphonamide useful in the preparation of the first mentioned physical form. The compositions are useful in the treatment of diseases in which leukotrienes are implicated, for example asthma.Patent expiration dates:
- December 11, 2011
- December 11, 2011
Pharmaceutical agents useful as leukotriene antagonists
Patent 5,482,963
Issued: January 9, 1996
Inventor(s): Holohan; James J. & Edwards; Ieuan J. & Timko; Robert J. & Bradway; Randy J. & Clements; Arlene
Assignee(s): Zeneca Limited
The invention provides a pharmaceutical composition comprising a particular physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide and polyvinylpyrrolidone. It also provides methods for preparing this physical form, and another physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide useful in the preparation of the first mentioned physical form. The compositions are useful in the treatment of diseases in which leukotrienes are implicated, for example asthma.Patent expiration dates:
- January 9, 2013
- January 9, 2013
Method of enhancing bioavailability of pharmaceutical agents
Patent 5,612,367
Issued: March 18, 1997
Inventor(s): Timko; Robert J. & Bradway; Randy J. & Clements; Arlene
Assignee(s): Zeneca Limited
The invention provides a pharmaceutical composition comprising a particular physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide and polyvinylpyrrolidone. It also provides methods for preparing this physical form, and another physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide useful in the preparation of the first mentioned physical form. The compositions are useful in the treatment of diseases in which leukotrienes are implicated, for example asthma.Patent expiration dates:
- March 18, 2014✓
- March 18, 2014
Process for preparing pharmaceutical composition containing a heterocyclic amide
Patent 6,143,775
Issued: November 7, 2000
Inventor(s): Holohan; James Joseph & Edwards; Ieuan John
Assignee(s): Zeneca Limited
The invention provides a pharmaceutical composition comprising a particular physical form of N-[4-[5-(cyclopentyloxy-carbonyl)amino-1-methylindol-3-yl-methyl]-3-methox ybenzoyl]-2-methyl-benzenesulphonamide and polyvinylpyrrolidone. It also provides methods for preparing this physical form, and another physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide useful in the preparation of the first mentioned physical form. The compositions are useful in the treatment of diseases in which leukotrienes are implicated, for example asthma.Patent expiration dates:
- December 11, 2011
- December 11, 2011
See also...
- Accolate Consumer Information (Wolters Kluwer)
- Accolate Consumer Information (Cerner Multum)
- Accolate Advanced Consumer Information (Micromedex)
- Accolate AHFS DI Monographs (ASHP)
- Zafirlukast Consumer Information (Wolters Kluwer)
- Zafirlukast Consumer Information (Cerner Multum)
- Zafirlukast Advanced Consumer Information (Micromedex)
- Zafirlukast AHFS DI Monographs (ASHP)
No comments:
Post a Comment